ACE2 and COVID-19: These changes will be provide the benefit for the recovery from heart and lung injury and dyspnea (Zhang et al., 2009; Singh et al., 2013; Yu et al., 2018 ; Gangwar et al., 2020), and the inhibitory effect of HIF-1α on ACE2 provides a novel idea for using IHP to treat COVID-19.